Literature DB >> 16307547

Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.

M Sumi, T Tauchi, G Sashida, N Shoji, A Gotoh, Y Itoh, K Miyazawa, Y Kimura, J H Ohyashiki, K Ohyashiki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16307547     DOI： 10.1111/j.1365-2257.2005.00723.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN： 0141-9854


× No keyword cloud information.
  5 in total

1.  Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

Authors:  Naoto Takahashi; Taiichi Kyo; Yasuhiro Maeda; Takashi Sugihara; Kensuke Usuki; Tatsuya Kawaguchi; Noriko Usui; Shinichiro Okamoto; Yokiko Ohe; Shigeki Ohtake; Kunio Kitamura; Masahide Yamamoto; Hirofumi Teshima; Toshiko Motoji; Toshiharu Tamaki; Kenichi Sawada; Kazuma Ohyashiki
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 2.  Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.

Authors:  Seiichi Okabe; Tetsuzo Tauchi; Yuko Ishii; Daigo Akahane; Kousuke Nunoda; Seiko Honda; Tomoiku Takaku; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

3.  Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.

Authors:  Kazuhisa Hosoya; Sakiko Mochinaga; Akiko Emoto; Hiromi Yokoo; Hideaki Tokushima; Masayoshi Egoshi; Naoko Sueoka-Aragane; Shinya Kimura
Journal:  Int J Clin Oncol       Date:  2015-05-23       Impact factor: 3.402

4.  Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia.

Authors:  Akiyoshi Takami; Shigeki Ohtake; Eriko Morishita; Yasushi Terasaki; Toshihiro Fukushima; Toshiro Kurokawa; Naomi Sugimori; Sadaya Matano; Kinya Ohata; Chizuru Saito; Masaki Yamaguchi; Kohei Hosokawa; Hirohito Yamazaki; Yukio Kondo; Shinji Nakao
Journal:  Int J Hematol       Date:  2012-08-15       Impact factor: 2.490

5.  A Rare t(9;22;16)(q34;q11;q24) Translocation in Chronic Myeloid Leukemia for Which Imatinib Mesylate Was Effective: A Case Report.

Authors:  Masahiro Manabe; Yumi Yoshii; Satoru Mukai; Erina Sakamoto; Hiroshi Kanashima; Takeshi Inoue; Hirofumi Teshima
Journal:  Leuk Res Treatment       Date:  2011-07-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.